Whilst many parameters connected to developing and manufacturing process that might predispose monoclonal antibodies to cause immune response are well known and appropriate steps are taken to monitor and control these unwanted effects, complications linked with administration of monoclonal antibodies to genetically diverse human population are less well described.
Although many variables connected to the production and manufacturing processes of monoclonal antibodies that might trigger an immune response are already recognized and steps are being taken to prevent them, the issues associated with administering these antibodies to people from different genetic backgrounds have not been as extensively explored.